- Home
- BESS vs MDXH Comparison
BESS vs MDXH Comparison
Compare BESS & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BESS | MDXH |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 15.0M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BESS | MDXH |
|---|---|---|
| Price | $2.91 | $0.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 6 |
| Target Price | ★ $8.50 | $0.83 |
| AVG Volume (30 Days) | 268.8K | ★ 1.9M |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $168,880.00 | N/A |
| Revenue This Year | N/A | $5.79 |
| Revenue Next Year | $206.88 | $12.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.52 | $0.14 |
| 52 Week High | $6.45 | $4.34 |
Technical Indicators
Market Signals| Indicator | BESS | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 25.57 |
| Support Level | $2.75 | N/A |
| Resistance Level | $3.17 | $0.64 |
| Average True Range (ATR) | 0.45 | 0.02 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 42.81 | 31.75 |
Price Performance
Historical ComparisonAbout BESS Bimergen Energy Corporation Common Stock
Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.